Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

ATP synthase subunit beta, mitochondrial

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase III

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Amyotrophic lateral sclerosis

3

Stroke

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

University of Virginia

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

EPA CompTox

3

FDA UNII

3

PUBCHEM

3

SMS_ID

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DEXPRAMIPEXOLE

WI638GUS96

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

ATP synthase subunit beta, mitochondrial

Conditions:

Amyotrophic lateral sclerosis

Dexpramipexole (also known as KNS-760704/R-pramipexole) was originally developed by University of Virginia researchers to treat Amyotrophic Lateral Sclerosis and then was licensed to global biotechnology company Biogen Idec for further development. H...

owever, on phase III clinical trial the study of this drug was discontinued. Biogen said the drug neither slowed the loss of muscle function nor prolonged the lives of patients with ALS, often called Lou Gehrig’s disease. Nor did it show any efficacy in secondary endpoints of the clinical trial, or work in any sub-group of patients—about a big a failure as a company could have a Phase III trial. In addition, was discovered, that dexpramipexole was able to bind to beta-subunit of the mitochondrial F1/FO ATP synthase complex and increased its activity, thus reduced ischemic brain injury. These findings, together with the excellent brain penetration and favorable safety profile in humans, make dexpramipexole a drug with realistic translational potential for the treatment of stroke.

DEXPRAMIPEXOLE DIHYDROCHLORIDE

795J01AE70

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

ATP synthase subunit beta, mitochondrial

Conditions:

Amyotrophic lateral sclerosis

Dexpramipexole (also known as KNS-760704/R-pramipexole) was originally developed by University of Virginia researchers to treat Amyotrophic Lateral Sclerosis and then was licensed to global biotechnology company Biogen Idec for further development. H...

owever, on phase III clinical trial the study of this drug was discontinued. Biogen said the drug neither slowed the loss of muscle function nor prolonged the lives of patients with ALS, often called Lou Gehrig’s disease. Nor did it show any efficacy in secondary endpoints of the clinical trial, or work in any sub-group of patients—about a big a failure as a company could have a Phase III trial. In addition, was discovered, that dexpramipexole was able to bind to beta-subunit of the mitochondrial F1/FO ATP synthase complex and increased its activity, thus reduced ischemic brain injury. These findings, together with the excellent brain penetration and favorable safety profile in humans, make dexpramipexole a drug with realistic translational potential for the treatment of stroke.

DEXPRAMIPEXOLE DIHYDROCHLORIDE ANHYDROUS

I9038PKO43

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

ATP synthase subunit beta, mitochondrial

Conditions:

Amyotrophic lateral sclerosis

Dexpramipexole (also known as KNS-760704/R-pramipexole) was originally developed by University of Virginia researchers to treat Amyotrophic Lateral Sclerosis and then was licensed to global biotechnology company Biogen Idec for further development. H...

owever, on phase III clinical trial the study of this drug was discontinued. Biogen said the drug neither slowed the loss of muscle function nor prolonged the lives of patients with ALS, often called Lou Gehrig’s disease. Nor did it show any efficacy in secondary endpoints of the clinical trial, or work in any sub-group of patients—about a big a failure as a company could have a Phase III trial. In addition, was discovered, that dexpramipexole was able to bind to beta-subunit of the mitochondrial F1/FO ATP synthase complex and increased its activity, thus reduced ischemic brain injury. These findings, together with the excellent brain penetration and favorable safety profile in humans, make dexpramipexole a drug with realistic translational potential for the treatment of stroke.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1